Kwon Mijung, Libutti Steven K
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA.
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):26-32. doi: 10.1016/j.ijrobp.2005.03.024.
Tumors, in most cases, need angiogenesis for their sustained growth. A great deal of evidence has suggested that the process of angiogenesis is regulated by the balance between proangiogenic and antiangiogenic factors. Thus, the inhibition of tumor angiogenesis has been considered to be one of the key targets in anticancer therapy, and more than 60 antiangiogenic compounds are currently under clinical evaluation in cancer patients. However, the molecular mechanisms responsible for the activity of many of these antiangiogenic compounds are still not well understood. The recent development of microarray technology has allowed us to investigate the mechanism of action of these inhibitors more rapidly and extensively. With the use of microarray technology, novel molecules and pathways are shown to play a role in angiogenesis. This article also reviews new experimental approaches combined with microarray analysis to identify the molecular pathways involved in tumor-host interactions. Elucidation of the pathways that mediate both angiogenic and antiangiogenic responses will help us to develop better anticancer therapies.
在大多数情况下,肿瘤的持续生长需要血管生成。大量证据表明,血管生成过程受促血管生成因子和抗血管生成因子之间平衡的调节。因此,抑制肿瘤血管生成被认为是抗癌治疗的关键靶点之一,目前有60多种抗血管生成化合物正在癌症患者中进行临床评估。然而,许多这些抗血管生成化合物活性的分子机制仍未得到充分了解。微阵列技术的最新发展使我们能够更快速、广泛地研究这些抑制剂的作用机制。通过使用微阵列技术,发现了新的分子和途径在血管生成中发挥作用。本文还综述了结合微阵列分析的新实验方法,以确定参与肿瘤-宿主相互作用的分子途径。阐明介导血管生成和抗血管生成反应的途径将有助于我们开发更好的抗癌疗法。